Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 9.28 -2.21% -0.21
XENE closed down 2.21 percent on Monday, March 18, 2019, on 67 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical XENE trend table...

Date Alert Name Type % Chg
Mar 18 Fell Below 200 DMA Bearish 0.00%
Mar 18 Overbought Stochastic Strength 0.00%
Mar 15 Inside Day Range Contraction -2.21%
Mar 15 Overbought Stochastic Strength -2.21%
Mar 14 Crossed Above 200 DMA Bullish -5.60%
Mar 14 180 Bullish Setup Bullish Swing Setup -5.60%
Mar 14 Pocket Pivot Bullish Swing Setup -5.60%
Mar 14 Overbought Stochastic Strength -5.60%
Mar 14 Upper Bollinger Band Touch Strength -5.60%
Mar 13 Fell Below 200 DMA Bearish 0.11%

Older signals for XENE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Gene Therapy Acne Osteoarthritis Cardiovascular Disease Analgesics Genentech Treatment Of Osteoarthritis Indoles Lipoprotein Lipase Deficiency Alipogene Tiparvovec Glybera Postherpetic Neuralgia
Is XENE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.92
52 Week Low 4.45
Average Volume 95,494
200-Day Moving Average 9.4152
50-Day Moving Average 8.3228
20-Day Moving Average 8.8365
10-Day Moving Average 9.25
Average True Range 0.5297
ADX 44.27
+DI 27.6332
-DI 7.5399
Chandelier Exit (Long, 3 ATRs ) 8.4109
Chandelier Exit (Short, 3 ATRs ) 9.1691
Upper Bollinger Band 10.0413
Lower Bollinger Band 7.6317
Percent B (%b) 0.68
BandWidth 27.268715
MACD Line 0.3728
MACD Signal Line 0.3375
MACD Histogram 0.0353
Fundamentals Value
Market Cap 167.01 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -5.59
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.08
Resistance 3 (R3) 10.15 9.97 9.94
Resistance 2 (R2) 9.97 9.76 9.93 9.90
Resistance 1 (R1) 9.62 9.64 9.53 9.55 9.85
Pivot Point 9.44 9.44 9.39 9.40 9.44
Support 1 (S1) 9.09 9.23 9.00 9.02 8.71
Support 2 (S2) 8.91 9.11 8.87 8.66
Support 3 (S3) 8.56 8.91 8.62
Support 4 (S4) 8.49